http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012519170-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0058 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01T1-161 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N21-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2010-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2012-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2012519170-A |
| titleOfInvention | INSITU method for monitoring EMT status of tumor cells in vivo |
| abstract | The present invention provides a method for determining in situ the EMT status of a patient's tumor cells in vivo, including: (a) an antibody that binds to a biomarker of EMT status, and a reporter molecule. Providing an EMT status detection complex; (b) introducing the complex into a tumor patient such that the complex contacts the EMT status biomarker of the tumor cell; (c) a signal from the complex at the tumor site And (d) using image analysis means to locate and quantify the signal from the complex at the tumor site, wherein the positive signal indicates that the EMT status biomarker is epithelial The biomarker indicates the presence of epithelial tumor cells, and the EMT status biomarker indicates the presence of mesenchymal tumor cells if it is a mesenchymal biomarker. Such methods are used to diagnose patients who may benefit from treatment with drugs such as EGFR or IGF-1R kinase inhibitors, and to prevent tumor cells from undergoing epithelial to mesenchymal changes. Useful for identifying and testing drugs that inhibit. The present invention is also, in place of an antibody, that binds to the EMT status biomarker Affibody (R) molecules is used, also provides the above methods. [Selection] Figure 1 |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019167363-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016528168-A |
| priorityDate | 2009-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1989.